Cardiovascular, Renal and Metabolism
Saving lives by jointly addressing cardio-renal-metabolic risks
Our distinctive approach to CVRM
Our core mission is to save the lives of patients by jointly addressing their cardio-renal-metabolic risks. Science is uncovering commonalities between cardiovascular (CV), renal and metabolic diseases (CVRM), explaining why reducing CV risk is so complex. With this knowledge, we are daring to do things differently by shifting focus from treating patients with a single disease, to addressing overlapping disease areas and risk factors.
Our focus is making sure every decision and development is rooted in our ambition to follow the science. We seek to produce medicines that not only provide superior efficacy compared to current treatments in their core indications, but that also help address associated complications.
Our scientific goal is to slow the progression of CV-related disease, and ultimately, modify or even halt the natural course of the disease itself and regenerate organs.
Our focus on unmet needs
Signs and symptoms do exist for moderate to severe atherosclerosis; however, it may not be diagnosed until after a heart attack or stroke.
There are 38 million heart failure patients worldwide, with many suffering from at least one other underlying condition such as type-2 diabetes.
Chronic Kidney Disease (CKD) is a complex, debilitating condition with 200 million adults diagnosed worldwide.
Diabetes is a growing disease and an enormous global burden that is currently projected to affect more than 592 million people by the year 2035.
Addressing the growing unmet need in CVRM
Learn more about our ambition and work in CVRM
Our CVRM pipeline
We have more than 25 therapies and therapy combinations in our early-to-late stage pipeline in CVRM.
MEDI0382 is a dual-peptide molecule that impacts insulin secretion and glucose homeostasis. It is under development for type-2 diabetes patients and may hold potential for other metabolic diseases.
MEDI5884 is designed to enhance reverse cholesterol transport and increase functional HDL. Its development is aimed to help prevent secondary CV events after a heart attack and may have potential for primary prevention in high-risk patients.
Cardiovascular, Renal and Metabolism (as at 18 May 2018)
Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. You should visit your local AstraZeneca site to find out more about our medicines in your country. In some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
Collaboration in CVRM
We are dedicated to engaging with partners in the scientific community to strengthen our commitment to following the science.
Healthy Heart Africa
Launched in Kenya in 2014 and Ethiopia in 2016, Healthy Heart Africa (HHA) is our leading access to medicines programme. Through HHA we are helping to tackle a silent killer in parts of the world where access to healthcare is at its lowest. Working in collaboration with each of the national Ministry of Health departments, HHA aspires to reach 10 million people with high blood pressure across Africa by 2025.
Joslin Diabetes Center
We are collaborating with the Joslin Diabetes Center at the Harvard Medical School to identify novel factors that could enhance pancreatic beta cell mass and function, or reverse beta cell dysfunction, to potentially prevent or stop the progression of diabetes. Three initial projects have been identified, focusing on several key areas including protecting and regenerating the insulin producing beta cells, with the potential for more projects to be added as new compelling science is identified.
To assist with our commitment to developing new therapies for the prevention and treatment of diabetes, obesity and related metabolic disorders, we have entered a research alliance with Michigan Medicine. Our researchers will utilise cutting-edge technologies to study genetic models and identify targets for treatment.
Sharing clinical trials information
New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 Inhibitors
US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
1. Mayo Clinic. Arteriosclerosis / atherosclerosis. http://www.mayoclinic.org/diseases-conditions/arteriosclerosis-atherosclerosis/symptoms-causes/dxc-20167022. Accessed 15 August 2017.
2. Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015; 385 (9970): 812-824.
3. Ojo A. Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translational Research. Transactions of the American Clinical and Climatological Association. 2014; 125: 229-246.
4. Guariguata L. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Research and Clinical Practice. 2014; 103: 137-149
5. World Health Organization. Global NCD Target: Reduce High Blood Pressure. http://www.who.int/beat-ncds/take-action/policy-brief-reduce-highblood-pressure.pdf
Accessed 15 August 2017.
Veeva ID: Z4-9561
Date of next review: March 2020